Project Grant K22CA288802
Award Date 8/8/25
Completion Date 7/31/28
Dollars Obligated $158K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $154,642 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research on identifying conserved cancer-specific immunopeptide targets in metastatic colorectal cancer. The project aims to systematically elucidate the evolving immunopeptidome (peptides presented by HLA class I molecules) from patient-derived colorectal cancer organoids to reveal targetable...
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...
- This $333,504 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research at The Washington University in Missouri to elucidate the unique roles of myeloid cells within the peritoneal cavity and peritoneum during colorectal cancer peritoneal metastasis. The project aims to provide new insights into the dynamics and function of peritoneal myeloid cells, and explore their implications for immunotherapy. This 2-year research...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $164,500 to The Trustees of Columbia University in the City of New York to investigate the mechanisms by which the protein S100A9 mediates brain metastasis in epidermal growth factor receptor (EGFR)-mutant lung cancer. The key goals are to: Examine how S100A9 expression is epigenetically regulated by histone methylation and the MEIS1 transcription factor in brain metastasis-prone cells....
- This Cooperative Agreement award for $639,882, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research at the University of North Carolina at Chapel Hill to elucidate the molecular mechanisms of metastasis organ tropism in breast cancer. The key objectives are to: Identify molecular determinants of lung and liver organ-specific metastasis using a comprehensive dataset of human primary tumors and metastases, as well as genetically...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a "Spatial Profiling-Based Immune Hub Perturbation Platform" to improve immunotherapy for colorectal cancer. The $710,361 award to J. David Gladstone Institutes will fund research to create a novel experimental framework to systematically test and prioritize candidate genes and therapies based on their ability to induce effective anti-tumor immune hubs -...
- This $192,888 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports a research project at the University of Virginia (UVA) to investigate the use of normal colon organoids for identifying causal genetic variants associated with colorectal cancer risk. The key objectives of the project are to: 1) test the hypothesis that colorectal cancer GWAS genes are cell type-specific, and 2) determine the role of these genes within colon epithelial...
- This $640,583 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory to conduct research aimed at enhancing the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their anti-tumor immunity and improve treatment outcomes for patients with microsatellite stable metastatic colorectal cancer, who typically respond poorly...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611 to the University of Texas Health Science Center at Houston (UTHealth) to identify the role and signaling mechanisms of the GPR56 protein in colorectal cancer progression and therapy resistance. The project aims to develop and evaluate novel antibody-drug conjugates and combination therapies targeting GPR56 for the improved treatment of colorectal cancer. Key activities...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $487,468 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the role of protein palmitoylation in the progression of melanoma lung metastasis. The key objectives of the research project are to: Investigate how the palmitoyl transferase ZDHHC13 suppresses melanoma metastasis by stabilizing E-cadherin through palmitoylation...